Skip to Content

GMO Benchmark-Free Allocation III GBMFX

Analyst rating as of

Morningstar’s Analysis

Will GBMFX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Consistently out of step.

Senior Analyst


| |

GMO’s multi-asset team remains staunchly committed to its value-centric approach, but that rigidity has led to missteps in recent years. That, combined with rising fees, drive a Morningstar Analyst Rating downgrade to Neutral for all of GMO Benchmark Free’s share classes.

Unlock our full analysis with Morningstar Investor